# EDGAR Filing Document

**Accession Number:** 0001845337
**File Stem:** 0001193125-26-095178
**Filing Date:** 2026-3
**Character Count:** 28330
**Document Hash:** 4a23e19df5b6e7b2c07035c46e58bdaf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-095178.hdr.sgml**: 20260306

**ACCESSION NUMBER**: 0001193125-26-095178

**CONFORMED SUBMISSION TYPE**: SC TO-C

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260306

**DATE AS OF CHANGE**: 20260306

**GROUP MEMBERS**: SERVIER DETROIT INC.

**GROUP MEMBERS**: SERVIER PHARMACEUTICALS LLC

**GROUP MEMBERS**: SERVIER S.A.S

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Day One Biopharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001845337
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832415215
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92582
- **FILM NUMBER:** 26728638

**BUSINESS ADDRESS:**
- **STREET 1:** 1800 SIERRA POINT PARKWAY, SUITE 200
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 650 484-0899

**MAIL ADDRESS:**
- **STREET 1:** 1800 SIERRA POINT PARKWAY, SUITE 200
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Day One Biopharmaceuticals Holding Co LLC
- **DATE OF NAME CHANGE:** 20210209
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Day One Biopharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001845337
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832415215
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C

**BUSINESS ADDRESS:**
- **STREET 1:** 1800 SIERRA POINT PARKWAY, SUITE 200
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 650 484-0899

**MAIL ADDRESS:**
- **STREET 1:** 1800 SIERRA POINT PARKWAY, SUITE 200
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Day One Biopharmaceuticals Holding Co LLC
- **DATE OF NAME CHANGE:** 20210209

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE TO** 

**Tender Offer Statement under Section 14(d)(1) or 13(e)(1)** 

**of the Securities Exchange Act of 1934** 

## DAY ONE BIOPHARMACEUTICALS, INC.
**(Name of Subject Company (Issuer))** 

**SERVIER DETROIT INC.,** 

**(Names of Filing Persons (Offeror))** 

**a direct, wholly owned subsidiary of** 

**SERVIER PHARMACEUTICALS LLC,** 

**(Names of Filing Persons (Parent of Offeror))** 

**an indirect wholly owned subsidiary of** 

**SERVIER S.A.S** 

**(Names of Filing Persons (Parent of Offeror))** 

**Common stock, $0.001 par value per share** 

**(Title of Class of Securities)** 

**23954D109** 

**(CUSIP Number of Class of Securities)** 

**Deniz Razon** 

**Chief Business Officer** 

**Servier Pharmaceuticals LLC** 

**200 Pier Four Boulevard** 

**7th Floor** 

**Boston, MA 02110** 

**Telephone: (800) 807-6124** 

**(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)** 

***Copy to:***

**Piotr Korzynski** 

**Michael S. Pilo** 

**Michael F. DeFranco** 

**Michelle Carr** 

**Baker & McKenzie LLP** 

**300 East Randolph Street, Suite 5000** 

**Chicago, Illinois 60601** 

**Telephone: (312) 861-8000** 

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a
tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates: Check the appropriate boxes below to designate any transactions to which the statement relates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ Third-party tender offer subject to Rule 14d-1.

☐ Going-private transaction subject to Rule 13e-3.

☐ Issuer tender offer subject to Rule 13e-4.

☐ Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

------

This Tender Offer Statement on Schedule TO relates solely to preliminary communications made before the commencement of a planned tender offer by Servier S.A.S., a French *société par actions simplifiée* ("**Servier**"), Servier Pharmaceuticals LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of Servier ("**Parent**"), and Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("**Merger Sub**" and together with Servier and Parent, the "**Servier Parties**"), for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of Day One Biopharmaceuticals, Inc., a Delaware corporation (the "**Company**"), pursuant to the Agreement and Plan of Merger, dated as of March 6, 2026 (the "**Merger Agreement**"), by and among Servier, Parent, Merger Sub and the Company.

**Important Information for Investors and Security Holders** 

The tender offer for the issued and outstanding shares of common stock of the Company referred to in this announcement has not yet commenced. The description contained in this announcement is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that the Servier Parties will file with the U.S. Securities and Exchange Commission (the "**SEC**"). The solicitation and offer to buy the common stock of the Company will only be made pursuant to an offer to purchase and related tender offer materials. At the time the tender offer is commenced, the Servier Parties will file a tender offer statement on Schedule TO and thereafter the Company will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. ALL HOLDERS OF SHARES ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED AND SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.

The offer to purchase, the related letter of transmittal and the solicitation/recommendation statement will be made available for free at the SEC's website at www.sec.gov. Free copies of the offer to purchase, the related letter of transmittal and certain other tender offer documents will be made available by Servier and when available may be obtained by directing a request to the Information Agent for the tender offer which will be named in the Schedule TO. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company's internet website at https://ir.dayonebio.com/investorrelations or by contacting the Company's investor relations contact at <u>investors@dayonebio.com</u>.

In addition to the offer to purchase, the related letter of transmittal and certain other tender offer documents filed by the Servier Parties, as well as the solicitation/recommendation statement filed by the Company, the Company will also file annual, quarterly and current reports with the SEC. You may read and copy any reports or other information filed by the Servier Parties or the Company at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The Company's filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at <u>http://www.sec.gov</u>.

------

**Forward-Looking Statements** 

This announcement contains forward-looking statements that provide Servier's expectations or forecasts of future events such as new product introductions, product approvals and financial performance and forward-looking statements regarding Servier's proposed acquisition of the Company, including regarding prospective benefits of the proposed acquisition, regarding the anticipated occurrence, manner and timing of the proposed tender offer and the closing of the proposed acquisition, regarding the Company's product candidates and ongoing clinical and preclinical development, and regarding the accounting treatment of the potential acquisition under GAAP and its potential impact on Servier's financial results and financial guidance. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this announcement, including, without limitation, those regarding the Servier Parties' and the Company's financial positions, business strategies, plans and objectives of management for future operations (including development plans and objectives relating to the Servier Parties' and the Company's products), are forward-looking statements.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Servier's or the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that may affect future results include, among others, delay or failure of development projects, production or distribution problems; unexpected contract breaches or terminations; interest rate and currency exchange rate fluctuations; government-mandated or market-driven price decreases for Servier's products; introduction of competing products; Servier's ability to successfully market both new and existing products; exposure to product liability and other lawsuits; changes in reimbursement rules and governmental laws and related interpretation thereof; and unexpected growth in costs and expenses. Additional risks and uncertainties include, but are not limited to, risks related to the Servier Parties' ability to complete the transaction on the proposed terms and schedule; whether the tender offer conditions will be satisfied; whether sufficient shareholders of the Company tender their shares in the transaction; the outcome of legal proceedings that may be instituted against the Company and/or others relating to the transaction; the failure to receive (or delay in receiving) the required regulatory approvals relating to the transaction; the possibility that competing offers will be made; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from Servier's and the Company's clinical studies; whether and when drug applications may be filed in any jurisdictions for any potential indication for any of Servier's or the Company's pipeline assets; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such products will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any such products; competitive developments; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; risks related to future opportunities and plans for the Company and its products, including uncertainty of the expected financial performance of the Company and its products; disruption from the proposed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; and other uncertainties pertaining to the business of the Company, including those detailed in the Company's public filings with the SEC from time to time, including the Company's most recent Annual Report on Form 10-K for the year ended December 31, 2025 and its subsequent Quarterly Reports on Form 10-Q, when available.

------

The reader is cautioned not to unduly rely on these forward-looking statements. The forward-looking statements in this announcement and any oral presentations speak only as at the date of this announcement. The Servier Parties disclaim any intent or obligation to update or revise these forward-looking statements, or to confirm such statements to reflect subsequent events or circumstances after the date of the company release or in relation to actual results, other than as may be required under applicable law or applicable stock exchange regulations.

**Item 12. Exhibits** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| Exhibit 99.1 | [Joint Press Release, dated March 6, 2026.](d55904dex991.htm) |

---

## Exhibit 99.1

**Exhibit 99.1** 

---

| | |
|:---|:---|
| ![LOGO](g55904g0306121431906.jpg) | ![LOGO](g55904g0306121440152.jpg) |

---

**Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Transaction represents total equity value of approximately $2.5 billion** 

**Suresnes, France and Brisbane, California, March 6, 2026 –** Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The transaction remains subject to customary closing conditions and is expected to close in the second quarter of 2026.

This acquisition will reinforce Servier's position in oncology targeted therapies in line with its 2030 ambition to develop innovative treatments for patients with high unmet medical needs. It strengthens Servier's portfolio and expands its oncology pipeline with programs ranging from early stage to phase 3. The combination of Day One's scientific expertise with Servier's established global capabilities advances a shared commitment to delivering innovative solutions for patients worldwide.

"This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier's position in rare oncology," **said Olivier Laureau, President of Servier**. "It reflects our long-term commitment to investing in science that can make a meaningful difference for patients. This announcement is fully aligned with our 2030 ambition, and we believe that combining our expertise will accelerate innovation for people living with a rare cancer."

"Servier's successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One's mission to bring medicines to patients of all ages with life threatening diseases" **said Jeremy Bender, Ph.D., chief executive officer of Day One**. "Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low-grade glioma. Importantly, Servier's dedication to the rare disease community preserves the patient-first mindset that has defined our company since the beginning and has driven our deep commitment to the communities we serve."

------

---

| | |
|:---|:---|
| ![LOGO](g55904g0306121431906.jpg) | ![LOGO](g55904g0306121440152.jpg) |

---

**Transaction terms** 

Under the terms of the merger agreement, Servier will commence a cash tender offer to acquire all of the issued and outstanding shares of Day One's common stock for $21.50 per share in cash, representing a total equity value of approximately of $2.5 billion. The offer price represents a premium of approximately 68% over the closing price of Day One on March 5, 2026, and a premium of approximately 86% over the one-month volume weighted average price (VWAP) of Day One as of March 5, 2026.

Servier expects to fund the transaction through existing cash and investments.

The consummation of the tender offer is subject to certain customary closing conditions, including the tender by Day One shareholders of at least a majority of the issued and outstanding shares of Day One common stock and the receipt of U.S. antitrust clearance. Upon the successful completion of the tender offer, Servier will acquire any shares not acquired in the tender through a second-step merger for the same consideration per share paid in the tender offer. Day One's Board of Directors recommends that Day One shareholders tender their shares in the tender offer.

**Advisors** 

Goldman Sachs Bank Europe SE is serving as exclusive financial advisor to Servier<sup>,</sup> and Baker McKenzie is serving as legal counsel. Centerview Partners LLC is serving as the exclusive financial advisor to Day One, with Fenwick & West LLP serving as legal counsel.

**Contacts** 

**Servier Group** 

Laura Visserias

<u>laura.visserias.part@servier.com</u>

**Servier Pharmaceuticals (U.S.)** 

Paulina Bucko

<u>Paulina.bucko@servier.com</u> 

**Day One Biopharmaceuticals Media** 

<u>media@dayonebio.com</u> 

**Day One Biopharmaceuticals Investors** 

LifeSci Advisors, PJ Kelleher

<u>pkelleher@lifesciadvisors.com</u> 

**About Servier** 

Servier is an independent international pharmaceutical group governed by a foundation. With its governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle.

As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. The Group intends to offer targeted therapeutic solutions, particularly in rare cancers and neurological diseases, and invests nearly 20% of its brand-name sales in R&D.

------

---

| | |
|:---|:---|
| ![LOGO](g55904g0306121431906.jpg) | ![LOGO](g55904g0306121440152.jpg) |

---

Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion.

More information on the Group website: <u>servier.com</u>

Follow us on social media: <u>LinkedIn</u>, <u>Facebook</u>, <u>X</u>, <u>Instagram</u>

**About Day One Biopharmaceuticals** 

Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by "The Day One Talk" that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what's possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments.

Day One is based in Brisbane, California. For more information, please visit <u>www.dayonebio.com</u> or find the Company on <u>LinkedIn</u> or <u>X</u>.

**Cautionary Notice Regarding Forward-Looking Statements** 

This communication contains forward-looking statements relating to the proposed acquisition of Day One by Servier. These forward-looking statements are not based on historical fact and include statements regarding the ability of Day One and Servier to complete the transactions contemplated by the Merger Agreement, including the parties' ability to satisfy the conditions to the consummation of the tender offer (the "offer") contemplated thereby and the other conditions set forth in the Merger Agreement, statements about the expected timetable for completing the transaction, Day One and Servier's beliefs and expectations and statements about the benefits sought to be achieved by Servier's proposed acquisition of Day One, the potential effects of the acquisition on both Day One and Servier, and the possibility of any termination of the Merger Agreement. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as "may," "will," "should," "would," "expect," "plan," "intend," and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, future events and trends that Day One believes may affect the financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs of Day One. There can be no guarantee that such expectations and projections will prove accurate in the future.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Actual results may differ materially from current expectations because of risks associated with uncertainties as to the timing of the offer and the subsequent merger; uncertainties as to how many of Day One's stockholders will tender their shares in the offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the merger and the offer contemplated thereby may not be satisfied or waived; the effects of disruption from the transactions contemplated by the Merger Agreement on Day One's business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; and the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability. Moreover, Day One operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. Although Day One believes that the expectations reflected in such forward-looking statements are reasonable, it cannot guarantee future events, results, actions, levels of activity, performance or achievements, business and market conditions, the timing and results of any developments and whether the conditions to the closing of the proposed acquisition are

------

---

| | |
|:---|:---|
| ![LOGO](g55904g0306121431906.jpg) | ![LOGO](g55904g0306121440152.jpg) |

---

satisfied on the expected timetable or at all. Other risks that may affect the future results of Day One and Servier are identified in their respective filings with the Securities and Exchange Commission (the "SEC") or other public disclosures. These forward-looking statements speak only as of the date they are made, and Day One and Servier undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

**Additional Information about the Acquisition and Where to Find It** 

The offer referenced in this communication has not yet commenced. This communication is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Servier and the Purchaser will file with the SEC upon commencement of the offer. A solicitation and offer to buy outstanding shares of Day One will only be made pursuant to the tender offer materials that Servier and the Purchaser intend to file with the SEC. At the time the offer is commenced, Servier and the Purchaser will file with the SEC tender offer materials on Schedule TO, and Day One will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer.

THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF DAY ONE ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME), BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF DAY ONE SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal) will be made available to all stockholders of Day One at no expense to them under the "Investor Resources" section of Day One's website at https://ir.dayonebio.com/ or by email at investors@dayonebio.com , or by directing requests for such materials to the information agent for the offer, which will be named in the tender offer materials, and (once they become available) the tender offer materials as well as the Solicitation/Recommendation Statement will be mailed to the stockholders of Day One free of charge. Copies of the documents filed with the SEC by Day One will be available free of charge on Day One's website, https://ir.dayonebio.com/, or by contacting Day One's investor relations department at investors@dayonebio.com. The information contained in, or that can be accessed through, Day One's website is not a part of or incorporated by reference herein. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available for free on the SEC's website at www.sec.gov. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Day One files annual, quarterly, and current reports, proxy statements, and other information with the SEC. You may read any reports, statements, or other information filed by Servier or Day One with the SEC for free on the SEC's website at www.sec.gov.